Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA1190 July 2024

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Pazopanib		
Initial application Applications only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months. Prerequisites(tick boxes where appropriate)		
The patient has metastatic renal cell carcinoma and		
The patient is treatment naive or The patient has only received prior cytokine treatment or		
The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance and The cancer did not progress whilst on sunitinib		
and The patient has good performance status (WHO/ECOG grade 0-2) and The disease is of predominant clear cell histology and The patient has intermediate or poor prognosis defined as: Lactate dehydrogenase level > 1.5 times upper limit of normal or Haemoglobin level < lower limit of normal or Corrected serum calcium level > 10 mg/dL (2.5 mmol/L) or Interval of < 1 year from original diagnosis to the start of systemic therapy or Karnofsky performance score of less than or equal to 70 or 2 or more sites of organ metastasis		
Pazopanib to be used for a maximum of 3 months		
Prerequisites(tick boxes where appropriate) No evidence of disease progressic and	ical practitioner on the recommendation of a relevant	specialist. Approvals valid for 3 months.
Note: Pazopanib treatment should be stopped if disease progresses. Poor prognesis nationts are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognesis nationts are defined as having 1 or 2 of criteria 5.1-5.6.		

I confirm the above details are correct and that in signing this form I understand I may be audited.